Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2019 16:07 ET
|
Eyenovia, Inc.
NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
June 04, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Reports First Quarter 2019 Financial Results
May 14, 2019 06:30 ET
|
Eyenovia, Inc.
NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS-ASOA Annual Meeting
May 06, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results
May 01, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
March 27, 2019 06:30 ET
|
Eyenovia, Inc.
NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
March 13, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia to Participate in Two Upcoming Investor Conferences
March 04, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
February 25, 2019 08:30 ET
|
Eyenovia, Inc.
MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 ...
Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering
February 13, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...